Free Trial

ResMed (RMD) Stock Forecast & Price Target

ResMed logo
$284.23 +4.06 (+1.45%)
Closing price 03:59 PM Eastern
Extended Trading
$283.50 -0.73 (-0.26%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
12

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a sell rating, 3 have given a hold rating, 10 have given a buy rating, and 2 have given a strong buy rating for RMD.

Consensus Price Target

$274.83
-3.31% Downside
According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $274.83. The highest price target for RMD is $325.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted downside of -3.31% from the current price of $284.23.
Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

Sign Up

RMD Analyst Ratings Over Time

TypeCurrent Forecast
8/8/24 to 8/8/25
1 Month Ago
7/9/24 to 7/9/25
3 Months Ago
5/10/24 to 5/10/25
1 Year Ago
8/9/23 to 8/8/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$274.83$259.33$258.83$204.70
Forecasted Upside-3.31% Downside1.40% Upside5.59% Upside-4.43% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ResMed Stock vs. The Competition

TypeResMedMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-2.72% Downside26,418.88% Upside13.73% Upside
News Sentiment Rating
Positive News

See Recent RMD News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/1/2025William Blair
2 of 5 stars
 UpgradeStrong-Buy
8/1/2025UBS Group
4 of 5 stars
Laura Sutcliffe
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$285.00 ➝ $325.00+16.25%
8/1/2025Royal Bank Of Canada
3 of 5 stars
Craig Wong-Pan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$294.00 ➝ $300.00+7.31%
8/1/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jonathan Block
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$240.00 ➝ $270.00-3.42%
8/1/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anthony Petrone
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$270.00 ➝ $290.00+3.73%
8/1/2025KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Brett Fishbin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$274.00 ➝ $298.00+9.49%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Adam Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$248.00 ➝ $270.00-0.79%
5/20/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Bailey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetOverweight ➝ Overweight$286.00+16.50%
4/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Low
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$286.00 ➝ $290.00+22.49%
3/5/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mathieu Chevrier
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
1/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Matson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
1/16/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Thillainathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$280.00 ➝ $283.00+18.39%
9/26/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$240.00 ➝ $270.00+11.12%
9/24/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Rescott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/18/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Polark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingPeer Perform ➝ Underperform$180.00-28.25%
6/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/5/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$240.00 ➝ $165.00+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:46 PM ET.


Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 5, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • The current stock price is around $300, reflecting strong market interest and potential for growth.
  • Recent upgrades from multiple research firms indicate positive sentiment, with price targets raised significantly, suggesting confidence in the company's future performance.
  • Institutional investors and hedge funds own nearly 55% of the company's stock, indicating strong backing and confidence from major financial players.
  • ResMed Inc. has a solid dividend payout ratio of approximately 25%, which may appeal to income-focused investors looking for regular returns.
  • The company operates in the growing healthcare sector, focusing on innovative medical devices and cloud-based software, positioning it well for future demand.

ResMed
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • Insider selling of over 29,000 shares recently may raise concerns about the confidence of those closest to the company.
  • Despite positive ratings, one analyst has issued a sell rating, indicating potential risks that some investors may want to consider.
  • The competitive landscape in the medical device industry is intense, which could impact ResMed Inc.'s market share and profitability.
  • Market volatility can affect stock performance, and recent fluctuations may lead to uncertainty for investors.
  • While the dividend payout is attractive, it is essential to monitor the company's ability to maintain or grow this payout in the future, especially in a competitive market.

RMD Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $274.83, with a high forecast of $325.00 and a low forecast of $180.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 10 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RMD shares.

According to analysts, ResMed's stock has a predicted downside of -3.31% based on their 12-month stock forecasts.

Over the previous 90 days, ResMed's stock had 2 upgrades by analysts.

ResMed has been rated by research analysts at KeyCorp, Mizuho, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, and William Blair in the past 90 days.

Analysts like ResMed more than other "medical" companies. The consensus rating score for ResMed is 2.81 while the average consensus rating score for "medical" companies is 2.81. Learn more on how RMD compares to other companies.


This page (NYSE:RMD) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners